Results 201 to 210 of about 70,621 (279)

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning, Balagopal Pai, Maike Collienne, Isabel Ben‐Batalla, Sonja Loges   +4 more
wiley   +1 more source

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice [PDF]

Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Giovanni Mariani, D. Aldrighetti, Giampaolo Bianchini, Luca Licata   +12 more
openalex   +1 more source

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer. [PDF]

Breast Cancer Res Treat
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, Díez AF, Henarejos PS, de la Morena Barrio P, Boix AP, Jiménez MD, Siles JP, Maestre JAP, de Las Heras-Rubio A, Carreño PR.   +12 more
europepmc   +1 more source

Frizzled‐9 Expression Is Associated With Aggressive Clinicopathological Features and Reduced Overall Survival in Invasive Breast Carcinoma

Pathology International, Volume 76, Issue 3, March 2026.
Graphical summary illustrating the evaluation of FZD9 in breast cancer. FZD9 protein expression was assessed by immunohistochemistry in 81 breast tumor samples and further investigated in breast cancer cell lines exposed to cytotoxic and epigenetic treatments. Higher FZD9 expression was associated with aggressive clinicopathological features and poorer
Daniel Rodrigues de Bastos, Ricardo Cesar Cintra, Adhemar Longatto‐Filho, Lara Termini   +3 more
wiley   +1 more source

The Association Between Alignment to the Breast Cancer Optimal Care Pathways and Patient Survival in Victoria, Australia, 2012–2019: A Retrospective Population‐Based Cohort Study

Medical Journal of Australia, Volume 224, Issue 3, March 2026.
ABSTRACT Objectives To quantify the association between care alignment to the treatment step of the Cancer Council Victoria and Department of Health Victoria Optimal care pathways for people with breast cancer (OCP) (second edition) and survival.
Brandon S. Hao, Juan C. Quiroz, Ian N. Olver, Claire M. Vajdic   +3 more
wiley   +1 more source

Reply to "Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions" and "The Role of HER2 PET in Treatment of Breast Cancer". [PDF]

J Nucl Med
Yeh R.
europepmc   +1 more source

Anti-HER2-targeted therapies: effects on human <i>in vitro</i> blood-brain barrier models. [PDF]

Front Drug Deliv
Curtaz CJ, Gebert R, Wöckel A, Meybohm P, Burek M.   +4 more
europepmc   +1 more source

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates. [PDF]

Biomed Chromatogr
Buitelaar PLM, Rosing H, Beijnen JH, Steeghs N, Huitema ADR.   +4 more
europepmc   +1 more source

High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses. [PDF]

Breast Cancer Res
Cohen EN, Gao H, Tin S, Wu Q, Ivan C, Ueno NT, Woodward WA, Reuben JM, Anfossi S.   +8 more
europepmc   +1 more source